All of the following drugs can be used for the chronic oral treatment of arrhythmia except:
First, the core concept here is the classification of antiarrhythmic drugs. The Vaughan Williams classification divides them into classes I to IV. Each class has different mechanisms of action and indications. For example, Class I drugs block sodium channels, Class II are beta-blockers, Class III are potassium channel blockers, and Class IV are calcium channel blockers.
Now, the correct answer would be a drug that's not used for chronic oral treatment. Let's think about common antiarrhythmics. Amiodarone (Class III) is used long-term. Beta-blockers like metoprolol (Class II) are also used orally. Calcium channel blockers like verapamil (Class IV) are used for certain arrhythmias. Lidocaine is a Class I drug but is typically used intravenously for acute arrhythmias, not orally for chronic treatment. So if one of the options is lidocaine, that would be the exception.
Wait, but lidocaine is a local anesthetic and is used for acute management. So if the options include lidocaine, that's the correct answer. Let me check the other drugs. Procainamide is Class Ia and can be oral. Flecainide (Class Ic) is oral. So if the options are A. Amiodarone, B. Metoprolol, C. Lidocaine, D. Verapamil, then the answer is C.
Now, the explanation. The core concept is the chronic use of antiarrhythmics. The correct answer is Lidocaine because it's used intravenously for acute cases. The incorrect options are all used orally. Clinical pearl: Remember that Class Ia, Ib, Ic, II, III, IV have different routes. Lidocaine is an Ib drug, used IV. So the answer is C.
**Core Concept**
The question tests knowledge of antiarrhythmic drug classification and their chronic oral use. Key drugs include beta-blockers (Class II), sodium channel blockers (Class I), potassium channel blockers (Class III), and calcium channel blockers (Class IV). Chronic oral therapy requires drugs with acceptable safety profiles for long-term use.
**Why the Correct Answer is Right**
**Lidocaine** is a **Class Ib sodium channel blocker** primarily used for **acute intravenous treatment** of ventricular arrhythmias (e.g., ventricular tachycardia). It lacks oral bioavailability due to rapid first-pass metabolism and is not approved for chronic oral use. Its short half-life and risk of proarrhythmia further limit long-term application.
**Why Each Wrong Option is Incorrect**
**Option A: Amiodarone** β A Class III antiarrhythmic with noncompetitive beta-blocking and calcium channel-blocking effects. It is a cornerstone for chronic arrhythmia management due to its broad-spectrum efficacy.
**Option B: Metoprolol** β A selective beta-1 blocker (Class II) used orally for long-term